By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics said Tuesday after the close of market that revenues for its fiscal fourth quarter rose 9 percent, with its women's health revenues bouncing 16 percent year over year.

The company also said that revenues rose 11 percent for full-year 2010 from full-year 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.